Menu Search
Equities

Xenon Pharmaceuticals Inc

XP0:FRA

Xenon Pharmaceuticals Inc

Actions
  • Price (EUR)40.60
  • Today's Change-0.600 / -1.46%
  • Shares traded85.00
  • 1 Year change+51.49%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.

  • Revenue in USD (TTM)0.00
  • Net income in USD-199.06m
  • Incorporated2000
  • Employees251.00
  • Location
    Xenon Pharmaceuticals Inc3650 Gilmore WayVANCOUVER V5G 4W8CanadaCAN
  • Phone+1 (604) 484-3300
  • Fax+1 (604) 484-3450
  • Websitehttps://www.xenon-pharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.